Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes |
| |
| Authors: | Susanne Trost MD Richard E. Pratley MD Burton E. Sobel MD |
| |
| Affiliation: | (1) Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, One South Prospect Street, 05401 Burlington, VT, USA |
| |
| Abstract: | Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
